Form 4: Pfizer Director Cyrus Taraporevala Receives Stock Units
Director Compensation Disclosure
Pfizer Inc. director Cyrus Taraporevala was granted 7,686.539 phantom stock units as part of the company's deferred compensation plan.
Summary
- Director Cyrus Taraporevala acquired 7,686.539 phantom stock units on April 23, 2026.
- The units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
- Each phantom unit represents one share of common stock, valued at $26.67 per unit.
- Following this transaction, the director holds a total of 34,826.086 phantom stock units.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.
Positives
- Director alignment with long-term company performance through equity-based compensation.
Negatives
- None identified; this is a standard director compensation disclosure.
Risks
- Value of phantom stock units is subject to fluctuations in Pfizer's common stock price.
Future Outlook
The units are settled in cash or common stock at the director's election following their retirement from the Board of Directors.
Management Comments
- The units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.
Industry Context
StockSavvy.ai notes that director compensation via deferred stock units is a standard corporate governance practice among large-cap pharmaceutical companies to ensure board members maintain a vested interest in long-term shareholder value.
Comparison to Industry Standards
- The use of phantom stock units for non-employee directors is consistent with compensation structures at peer companies like Merck, Bristol Myers Squibb, and Eli Lilly.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of phantom stock units under the Nonfunded Deferred Compensation and Unit Award Plan. | 04/23/2026 | Standard alignment of director interests with shareholders. |
Stakeholder Impact
- Minimal impact on shareholders as this is a routine compensation event.
Next Steps
- The director will hold these units until retirement from the Board of Directors.
Key Dates
| Date | Description |
|---|---|
| 04/23/2026 | Date of the phantom stock unit grant transaction. |
| 04/27/2026 | Date the Form 4 was filed with the SEC. |
Keywords
Pfizer, PFE, Director Compensation, Form 4, Insider Transaction, Phantom Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.